Our Products
Opsona Therapeutics is developing a number of highly innovative products to modulate the human immune system.
Our ability to deliver is reflected in our partnerships with global companies such as Wyeth/Pfizer and CSL and investors including GenenFUND and the Novartis and Roche Venture Funds.
Our Research
Our research is focused on using targeted approaches to explore the role of Toll-Like Receptors in innate immune pathways.
A large body of recent ground breaking scientific research suggests that better understanding TLRs and TLR signalling, and applying this knowledge is an attractive, innovative approach to developing improved drugs for the treatment of autoimmune and inflammatory conditions, cancers and infectious diseases.
latest news
Opsona Therapeutics announces the issuance of new patent from the European Patent Office (EPO) covering the development and use of an antibody directed against Toll-like Receptor TLR-2
Opsona Therapeutics, the innate immune drug development company, today announced that the European Patent Office has issued EP Patent 1,664,118 which covers an antibody directed against Toll-like Receptor TLR-2 and the use and development thereof.
Opsona Appoints Dr Martin Welschof as CEO and Conor Dalton as Director of Finance
Experienced biopharmaceutical executives form new leadership team at innate immune drug development company
Opsona Therapeutics announces initiation of a Phase 1 clinical trial with its lead drug
Opsona Therapeutics announces initiation of a Phase 1 clinical trial with its lead drug
candidate OPN-305, a first-in-class antibody against Toll-like-Receptor-2